46887615_2_Diabetes_Therapy_if_Approved__5
[0] DPP4 inhibitors [1] Januvia, [2] Slow breakdown of GLP-1, which increases post-prandial insulin release [3] No hypoglycemia, weight neutral, sustained efficacy, side effects uncommon [4] Expensive [5] 
Gaining traction as a second or third medication after metformin
Where Will Invokana (canagliflozin) Fit in Type 2 Diabetes Therapy if Approved
5